{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:54:19Z","timestamp":1793084059110,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T00:00:00Z","timestamp":1709856000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100006484","name":"Vifor Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006484","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Pfizer Pharma GmbH"},{"DOI":"10.13039\/501100014841","name":"Medac","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014841","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Johann Wolfgang Goethe-Universit\u00e4t, Frankfurt am Main"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2024,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Although addition of adjuvant chemotherapy is the current standard, the prognosis of pancreatic cancers still remains poor. The NEPAFOX trial evaluated perioperative treatment with FOLFIRINOX in resectable pancreatic cancer.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Patients and Methods<\/jats:title>\n                <jats:p>This multicenter phase II trial randomized patients with resectable or borderline resectable pancreatic cancer without metastases into arm (A,) upfront surgery plus adjuvant gemcitabine, or arm (B,) perioperative FOLFIRINOX. The primary endpoint was overall survival (OS).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Owing to poor accrual, recruitment was prematurely stopped after randomization of 40 of the planned 126 patients (A: 21, B: 19). Overall, approximately three-quarters were classified as primarily resectable (A: 16, B: 15), and the remaining patients were classified as borderline resectable (A: 5, B: 4). Of the 12 evaluable patients, 3 achieved partial response under neoadjuvant FOLFIRINOX. Of the 21 patients in arm A and 19 patients in arm B, 17 and 7 underwent curative surgery, and R0-resection was achieved in 77% and 71%, respectively. Perioperative morbidity occurred in 72% in arm A and 46% in arm B, whereas non-surgical toxicity was comparable in both arms. Median RFS\/PFS was almost doubled in arm B (14.1\u00a0months) compared with arm A (8.4\u00a0months) in the population with surgical resection, whereas median OS was comparable between both arms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Although the analysis was only descriptive owing to small patient numbers, no safety issues regarding surgical complications were observed in the perioperative FOLFIRINOX arm. Thus, considering the small number of patients, perioperative treatment approach appears feasible and potentially effective in well-selected cohorts of patients. In pancreatic cancer, patient selection before initiation of neoadjuvant therapy appears to be critical.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1245\/s10434-024-15011-7","type":"journal-article","created":{"date-parts":[[2024,3,8]],"date-time":"2024-03-08T19:02:00Z","timestamp":1709924520000},"page":"4073-4083","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Adjuvant Gemcitabine Versus Neoadjuvant\/Adjuvant FOLFIRINOX in Resectable Pancreatic Cancer: The Randomized Multicenter Phase II NEPAFOX Trial"],"prefix":"10.1245","volume":"31","author":[{"given":"Thorsten O.","family":"Goetze","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Reichart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulli S.","family":"Bankstahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Pauligk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Loose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas W.","family":"Kraus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moustafa","family":"Elshafei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolf O.","family":"Bechstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00f6rg","family":"Trojan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Behrend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Homann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marino","family":"Venerito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Bohle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Varvenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus","family":"Bolling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk M.","family":"Behringer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karsten","family":"Kratz-Albers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele M.","family":"Siegler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Hozaeel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salah-Eddin","family":"Al-Batran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,3,8]]},"reference":[{"key":"15011_CR1","unstructured":"NIH National Cancer Institute. Surveillance, epidemiology, and end results (SEER) program; 2022. https:\/\/seer.cancer.gov\/statfacts\/html\/pancreas.html. Accessed Jan 2023."},{"issue":"14","key":"15011_CR2","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1001\/jama.2013.279201","volume":"310","author":"H Oettle","year":"2013","unstructured":"Oettle H, Neuhaus P, Hochhaus A, et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial. JAMA. 2013;310(14):1473\u201381. https:\/\/doi.org\/10.1001\/jama.2013.279201.","journal-title":"JAMA"},{"issue":"5","key":"15011_CR3","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s11912-018-0685-y","volume":"20","author":"MT Roth","year":"2018","unstructured":"Roth MT, Berlin JD. Current concepts in the treatment of resectable pancreatic cancer. Curr Oncol Rep. 2018;20(5):39. https:\/\/doi.org\/10.1007\/s11912-018-0685-y.","journal-title":"Curr Oncol Rep"},{"issue":"12","key":"15011_CR4","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1016\/s1470-2045(16)30531-9","volume":"17","author":"S-E Al-Batran","year":"2016","unstructured":"Al-Batran S-E, Hofheinz RD, Pauligk C, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2\/3 trial. Lancet Oncol. 2016;17(12):1697\u2013708. https:\/\/doi.org\/10.1016\/s1470-2045(16)30531-9.","journal-title":"Lancet Oncol"},{"issue":"10184","key":"15011_CR5","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1016\/s0140-6736(18)32557-1","volume":"393","author":"S-E Al-Batran","year":"2019","unstructured":"Al-Batran S-E, Homann N, Pauligk C, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2\/3 trial. Lancet. 2019;393(10184):1948\u201357. https:\/\/doi.org\/10.1016\/s0140-6736(18)32557-1.","journal-title":"Lancet"},{"issue":"2","key":"15011_CR6","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1097\/sla.0000000000002705","volume":"268","author":"JY Jang","year":"2018","unstructured":"Jang JY, Han Y, Lee H, et al. Oncological benefits of neoadjuvant chemoradiation with gemcitabine versus upfront surgery in patients with borderline resectable pancreatic cancer: a prospective, randomized, open-label, multicenter phase 2\/3 trial. Ann Surg. 2018;268(2):215\u201322. https:\/\/doi.org\/10.1097\/sla.0000000000002705.","journal-title":"Ann Surg"},{"issue":"9","key":"15011_CR7","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1001\/jamaoncol.2022.2319","volume":"8","author":"MHG Katz","year":"2022","unstructured":"Katz MHG, Shi Q, Meyers J, et al. Efficacy of preoperative mFOLFIRINOX vs mFOLFIRINOX plus hypofractionated radiotherapy for borderline resectable adenocarcinoma of the pancreas: the A021501 phase 2 randomized clinical trial. JAMA Oncol. 2022;8(9):1263\u201370. https:\/\/doi.org\/10.1001\/jamaoncol.2022.2319.","journal-title":"JAMA Oncol"},{"key":"15011_CR8","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/j.ejca.2021.10.023","volume":"160","author":"JL van Dam","year":"2022","unstructured":"van Dam JL, et al. Neoadjuvant therapy or upfront surgery for resectable and borderline resectable pancreatic cancer: a meta-analysis of randomised controlled trials. Eur J Cancer. 2022;160:140\u20139. https:\/\/doi.org\/10.1016\/j.ejca.2021.10.023.","journal-title":"Eur J Cancer"},{"issue":"16","key":"15011_CR9","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1200\/jco.19.02274","volume":"38","author":"E Versteijne","year":"2020","unstructured":"Versteijne E, Suker M, Groothuis K, et al. Preoperative chemoradiotherapy versus immediate surgery for resectable and borderline resectable pancreatic cancer: results of the Dutch randomized phase III PREOPANC trial. J Clin Oncol. 2020;38(16):1763\u201373. https:\/\/doi.org\/10.1200\/jco.19.02274.","journal-title":"J Clin Oncol"},{"issue":"1","key":"15011_CR10","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.suc.2017.09.009","volume":"98","author":"RA Wolff","year":"2018","unstructured":"Wolff RA. Adjuvant or neoadjuvant therapy in the treatment in pancreatic malignancies: where are we? Surg Clin North Am. 2018;98(1):95\u2013111. https:\/\/doi.org\/10.1016\/j.suc.2017.09.009.","journal-title":"Surg Clin North Am"},{"issue":"4","key":"15011_CR11","doi-asserted-by":"publisher","first-page":"289","DOI":"10.21037\/hbsn.2018.03.11","volume":"7","author":"S Heinrich","year":"2018","unstructured":"Heinrich S. Neoadjuvant therapy for pancreatic ductal adenocarcinoma-real effects or patient selection? Hepatobiliary Surg Nutr. 2018;7(4):289\u201391. https:\/\/doi.org\/10.21037\/hbsn.2018.03.11.","journal-title":"Hepatobiliary Surg Nutr"},{"issue":"4","key":"15011_CR12","doi-asserted-by":"publisher","first-page":"e1000267","DOI":"10.1371\/journal.pmed.1000267","volume":"7","author":"S Gillen","year":"2010","unstructured":"Gillen S, Schuster T, Meyer Zum B\u00fcschenfelde C, Friess H, Kleeff J. Preoperative\/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med. 2010;7(4):e1000267. https:\/\/doi.org\/10.1371\/journal.pmed.1000267.","journal-title":"PLoS Med"},{"issue":"1","key":"15011_CR13","doi-asserted-by":"publisher","first-page":"15662","DOI":"10.1038\/s41598-019-52167-9","volume":"9","author":"YS Lee","year":"2019","unstructured":"Lee YS, Lee J-C, Yang SY, Kim J, Hwang J-H. Neoadjuvant therapy versus upfront surgery in resectable pancreatic cancer according to intention-to-treat and per-protocol analysis: a systematic review and meta-analysis. Sci Rep. 2019;9(1):15662\u201315662. https:\/\/doi.org\/10.1038\/s41598-019-52167-9.","journal-title":"Sci Rep"},{"issue":"4","key":"15011_CR14","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1007\/s00432-013-1572-4","volume":"140","author":"CP Xu","year":"2014","unstructured":"Xu CP, Xue XJ, Liang N, Xu DG, Liu FJ, Yu XS, Zhang JD. Effect of chemoradiotherapy and neoadjuvant chemoradiotherapy in resectable pancreatic cancer: a systematic review and meta-analysis. J Cancer Res Clin Oncol. 2014;140(4):549\u201359. https:\/\/doi.org\/10.1007\/s00432-013-1572-4.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"5","key":"15011_CR15","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1097\/sla.0000000000005126","volume":"274","author":"DL Birrer","year":"2021","unstructured":"Birrer DL, Golcher H, Casadei R, et al. Neoadjuvant therapy for resectable pancreatic cancer: a new standard of care pooled data from 3 randomized controlled trials. Ann Surg. 2021;274(5):713\u201320. https:\/\/doi.org\/10.1097\/sla.0000000000005126.","journal-title":"Ann Surg"},{"issue":"10073","key":"15011_CR16","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1016\/s0140-6736(16)32409-6","volume":"389","author":"JP Neoptolemos","year":"2017","unstructured":"Neoptolemos JP, Palmer DH, Ghaneh P, et al. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2017;389(10073):1011\u201324. https:\/\/doi.org\/10.1016\/s0140-6736(16)32409-6.","journal-title":"Lancet"},{"issue":"5","key":"15011_CR17","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1245\/s10434-011-2110-8","volume":"19","author":"A Andriulli","year":"2012","unstructured":"Andriulli A, Festa V, Botteri E, et al. Neoadjuvant\/preoperative gemcitabine for patients with localized pancreatic cancer: a meta-analysis of prospective studies. Ann Surg Oncol. 2012;19(5):1644\u201362. https:\/\/doi.org\/10.1245\/s10434-011-2110-8.","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"15011_CR18","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.jamcollsurg.2011.09.022","volume":"214","author":"SC Mayo","year":"2012","unstructured":"Mayo SC, Gilson MM, Herman JM, et al. Management of patients with pancreatic adenocarcinoma: national trends in patient selection, operative management, and use of adjuvant therapy. J Am Coll Surg. 2012;214(1):33\u201345. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2011.09.022.","journal-title":"J Am Coll Surg"},{"issue":"2","key":"15011_CR19","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1097\/sla.0000000000000378","volume":"260","author":"RP Merkow","year":"2014","unstructured":"Merkow RP, Bilimoria KY, Tomlinson JS, et al. Postoperative complications reduce adjuvant chemotherapy use in resectable pancreatic cancer. Ann Surg. 2014;260(2):372\u20137. https:\/\/doi.org\/10.1097\/sla.0000000000000378.","journal-title":"Ann Surg"},{"issue":"1","key":"15011_CR20","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.annonc.2022.09.161","volume":"34","author":"T Seufferlein","year":"2023","unstructured":"Seufferlein T, Uhl W, Kornmann M, et al. Perioperative or only adjuvant gemcitabine plus nab-paclitaxel for resectable pancreatic cancer (NEONAX)\u2014a randomized phase II trial of the AIO pancreatic cancer group. Ann Oncol. 2023;34(1):91\u2013100. https:\/\/doi.org\/10.1016\/j.annonc.2022.09.161.","journal-title":"Ann Oncol"},{"issue":"3","key":"15011_CR21","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1001\/jamaoncol.2020.7328","volume":"7","author":"DPS Sohal","year":"2021","unstructured":"Sohal DPS, Duong M, Ahmad SA, et al. Efficacy of perioperative chemotherapy for resectable pancreatic adenocarcinoma: a phase 2 randomized clinical trial. JAMA Oncol. 2021;7(3):421\u20137. https:\/\/doi.org\/10.1001\/jamaoncol.2020.7328.","journal-title":"JAMA Oncol"},{"issue":"11","key":"15011_CR22","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1200\/JCO.22.01134","volume":"41","author":"MA Tempero","year":"2023","unstructured":"Tempero MA, Pelzer U, O\u2019Reilly EM, et al. Adjuvant nab-paclitaxel + gemcitabine in resected pancreatic ductal adenocarcinoma: results from a randomized, open-label, phase III trial. J Clin Oncol. 2023;41(11):2007\u201319. https:\/\/doi.org\/10.1200\/JCO.22.01134.","journal-title":"J Clin Oncol."},{"issue":"21","key":"15011_CR23","doi-asserted-by":"publisher","first-page":"3496","DOI":"10.1200\/jco.2007.15.8634","volume":"26","author":"DB Evans","year":"2008","unstructured":"Evans DB, Varadhachary GR, Crane CH, et al. Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(21):3496\u2013502. https:\/\/doi.org\/10.1200\/jco.2007.15.8634.","journal-title":"J Clin Oncol"},{"issue":"1","key":"15011_CR24","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1007\/s00066-014-0737-7","volume":"191","author":"H Golcher","year":"2015","unstructured":"Golcher H, Brunner TB, Witzigmann H, et al. Neoadjuvant chemoradiation therapy with gemcitabine\/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phase II trial. Strahlenther Onkol. 2015;191(1):7\u201316. https:\/\/doi.org\/10.1007\/s00066-014-0737-7.","journal-title":"Strahlenther Onkol"},{"issue":"4","key":"15011_CR25","doi-asserted-by":"publisher","first-page":"683","DOI":"10.21037\/jgo.2017.04.01","volume":"8","author":"D Grose","year":"2017","unstructured":"Grose D, McIntosh D, Jamieson N, et al. The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. J Gastro Oncol. 2017;8(4):683\u201395. https:\/\/doi.org\/10.21037\/jgo.2017.04.01.","journal-title":"J Gastro Oncol"},{"issue":"15","key":"15011_CR26","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1200\/jco.2007.15.5556","volume":"26","author":"S Heinrich","year":"2008","unstructured":"Heinrich S, Pestalozzi BC, Sch\u00e4fer M, et al. Prospective phase II trial of neoadjuvant chemotherapy with gemcitabine and cisplatin for resectable adenocarcinoma of the pancreatic head. J Clin Oncol. 2008;26(15):2526\u201331. https:\/\/doi.org\/10.1200\/jco.2007.15.5556.","journal-title":"J Clin Oncol"},{"issue":"2","key":"15011_CR27","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1002\/ags3.12311","volume":"4","author":"F Motoi","year":"2020","unstructured":"Motoi F, Unno M. Neoadjuvant treatment for resectable pancreatic adenocarcinoma: what is the best protocol? Ann Gastroenterol Surg. 2020;4(2):100\u20138. https:\/\/doi.org\/10.1002\/ags3.12311.","journal-title":"Ann Gastroenterol Surg"},{"issue":"1","key":"15011_CR28","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1097\/SLA.0000000000000251","volume":"260","author":"EM O\u2019Reilly","year":"2014","unstructured":"O\u2019Reilly EM, Perelshteyn A, Jarnagin WR, et al. A single-arm, nonrandomized phase II trial of neoadjuvant gemcitabine and oxaliplatin in patients with resectable pancreas adenocarcinoma. Ann Surg. 2014;260(1):142\u20138. https:\/\/doi.org\/10.1097\/SLA.0000000000000251.","journal-title":"Ann Surg"},{"issue":"2","key":"15011_CR29","doi-asserted-by":"publisher","first-page":"343","DOI":"10.2214\/ajr.12.8862","volume":"200","author":"DV Sahani","year":"2013","unstructured":"Sahani DV, Kambadakone A, Macari M, Takahashi N, Chari S, Fernandez-del Castillo C. Diagnosis and management of cystic pancreatic lesions. AJR Am J Roentgenol. 2013;200(2):343\u201354. https:\/\/doi.org\/10.2214\/ajr.12.8862.","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"15011_CR30","doi-asserted-by":"publisher","first-page":"787","DOI":"10.3892\/etm.2012.482","volume":"3","author":"H Tajima","year":"2012","unstructured":"Tajima H, Ohta T, Kitagawa H, et al. Pilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancer. Exp Ther Med. 2012;3(5):787\u201392. https:\/\/doi.org\/10.3892\/etm.2012.482.","journal-title":"Exp Ther Med"},{"issue":"2","key":"15011_CR31","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1245\/aso.2006.03.039","volume":"13","author":"MS Talamonti","year":"2006","unstructured":"Talamonti MS, Small W Jr, Mulcahy MF, et al. A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol. 2006;13(2):150\u20138. https:\/\/doi.org\/10.1245\/aso.2006.03.039.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"15011_CR32","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1159\/000215928","volume":"76","author":"O Turrini","year":"2009","unstructured":"Turrini O, Viret F, Moureau-Zabotto L, et al. Neoadjuvant 5 fluorouracil-cisplatin chemoradiation effect on survival in patients with resectable pancreatic head adenocarcinoma: a ten-year single institution experience. Oncology. 2009;76(6):413\u20139. https:\/\/doi.org\/10.1159\/000215928.","journal-title":"Oncology"},{"issue":"2","key":"15011_CR33","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/jjco\/hyy190","volume":"49","author":"F Motoi","year":"2019","unstructured":"Motoi F, Kosuge T, Ueno H, et al. Randomized phase II\/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02\/JSAP05). Jpn J Clin Oncol. 2019;49(2):190\u20134. https:\/\/doi.org\/10.1093\/jjco\/hyy190.","journal-title":"Jpn J Clin Oncol."},{"issue":"25","key":"15011_CR34","doi-asserted-by":"publisher","first-page":"2395","DOI":"10.1056\/NEJMoa1809775","volume":"379","author":"T Conroy","year":"2018","unstructured":"Conroy T, Hammel P, Hebbar M, et al. FOLFIRINOX or gemcitabine as adjuvant therapy for pancreatic cancer. N Engl J Med. 2018;379(25):2395\u2013406. https:\/\/doi.org\/10.1056\/NEJMoa1809775.","journal-title":"N Engl J Med"},{"issue":"6","key":"15011_CR35","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/ijc.33336","volume":"148","author":"S-E Al-Batran","year":"2021","unstructured":"Al-Batran S-E, Hofheinz R-D, Reichart A, et al. Quality of life and outcome of patients with metastatic pancreatic cancer receiving first-line chemotherapy with nab-paclitaxel and gemcitabine: real-life results from the prospective QOLIXANE trial of the platform for outcome, quality of life and translational research on pancreatic cancer registry. Int J Cancer. 2021;148(6):1478\u201388. https:\/\/doi.org\/10.1002\/ijc.33336.","journal-title":"Int J Cancer"},{"key":"15011_CR36","unstructured":"Deutsche Krebsgesellschaft. Jahresbericht der zertifizierten Pankreaskarzinomzentren\u2014Kennzahlenauswertung 2018. Available online: www.krebsgesellschaft.de\/jahresberichte.html. Accessed Jan 2023."},{"issue":"1","key":"15011_CR37","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1097\/sla.0000000000000867","volume":"261","author":"CR Ferrone","year":"2015","unstructured":"Ferrone CR, Marchegiani G, Hong TS. Radiological and surgical implications of neoadjuvant treatment with FOLFIRINOX for locally advanced and borderline resectable pancreatic cancer. Ann Surg. 2015;261(1):12\u20137. https:\/\/doi.org\/10.1097\/sla.0000000000000867.","journal-title":"Ann Surg"},{"issue":"20","key":"15011_CR38","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1200\/jco.2017.72.4948","volume":"35","author":"AA Khorana","year":"2017","unstructured":"Khorana AA, Mangu PB, Berlin J, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol. 2017;35(20):2324\u20138. https:\/\/doi.org\/10.1200\/jco.2017.72.4948.","journal-title":"J Clin Oncol"},{"issue":"7","key":"15011_CR39","doi-asserted-by":"publisher","first-page":"3104","DOI":"10.1007\/s00330-016-4632-8","volume":"27","author":"M Wagner","year":"2017","unstructured":"Wagner M, Antunes C, Pietrasz D, et al. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma. Eur Radiol. 2017;27(7):3104\u201316. https:\/\/doi.org\/10.1007\/s00330-016-4632-8.","journal-title":"Eur Radiol"},{"key":"15011_CR40","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V. S3-Leitlinie zum exokrinen Pankreaskarzinom. (Version 1.0); 2013."},{"issue":"2","key":"15011_CR41","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1055\/s-0033-1356390","volume":"52","author":"T Seufferlein","year":"2014","unstructured":"Seufferlein T. Guidelines and expert consensus in the ZfG. Z Gastroenterol. 2014;52(2):179. https:\/\/doi.org\/10.1055\/s-0033-1356390.","journal-title":"Z Gastroenterol"},{"key":"15011_CR42","doi-asserted-by":"publisher","first-page":"50","DOI":"10.21037\/tgh.2019.06.02","volume":"4","author":"L Haeberle","year":"2019","unstructured":"Haeberle L, Esposito I. Pathology of pancreatic cancer. Transl Gastroenterol Hepatol. 2019;4:50. https:\/\/doi.org\/10.21037\/tgh.2019.06.02.","journal-title":"Transl Gastroenterol Hepatol"},{"issue":"2","key":"15011_CR43","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.gie.2011.08.049","volume":"75","author":"MJ Hewitt","year":"2012","unstructured":"Hewitt MJ, McPhail MJ, Possamai L, Dhar A, Vlavianos P, Monahan KJ. EUS-guided FNA for diagnosis of solid pancreatic neoplasms: a meta-analysis. Gastrointest Endosc. 2012;75(2):319\u201331. https:\/\/doi.org\/10.1016\/j.gie.2011.08.049.","journal-title":"Gastrointest Endosc"},{"issue":"1","key":"15011_CR44","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ctrv.2014.11.002","volume":"41","author":"C Verbeke","year":"2015","unstructured":"Verbeke C, L\u00f6hr M, Karlsson JS, Del Chiaro M. Pathology reporting of pancreatic cancer following neoadjuvant therapy: challenges and uncertainties. Cancer Treat Rev. 2015;41(1):17\u201326. https:\/\/doi.org\/10.1016\/j.ctrv.2014.11.002.","journal-title":"Cancer Treat Rev"}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15011-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-024-15011-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-024-15011-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,7]],"date-time":"2024-05-07T13:07:00Z","timestamp":1715087220000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-024-15011-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,3,8]]},"references-count":44,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["15011"],"URL":"https:\/\/doi.org\/10.1245\/s10434-024-15011-7","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,3,8]]},"assertion":[{"value":"31 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 March 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Thorsten O. Goetze consults for Amgen, AstraZeneca, Bayer, BMS, Daiichi Sankyo, Foundation One Medicine, Lilly, MCI, MSD, Novartis, Roche, and Boehringer and received honoraria from Amgen, BMS, Lilly, MSD, Novartis, Roche, and GSK. Wolf O. Bechstein received honoraria from Astellas, Charit\u00e9 Berlin, CHIESI, Deutscher \u00c4rzteverlag, Else-Kr\u00f6ner-Stiftung, European Society for Organ Transplantation, Falk Foundation, GORE, MCI, Novartis, Sanofi, Sirtex, and Terumo. Gabriele M. Siegler consults for AstraZeneca, BMS, Janssen-Cilag, Novartis; receives honoraria from Aurikamed, BMS, Deutsche R\u00f6ntgengesellschaft, Eisai, Janssen-Cilag, Konzept Pharma, Roche; research grants from Novartis and Nutricia; and travel grants from Amgen, Novarti, and Servier. Salah-Eddin Al-Batran is the CEO\/funder of Institut f\u00fcr Klinische Krebsforschung IKF; is on the advisory board of BMS, Immutep, Lilly, MacroGenics, and MSD; received research grants from Astra-Zeneca, BMS, Celgene, Eurozyto, Hospira, Immutep, Ipsen, Lilly, Medac, MSD, Roche, Sanofi, and Vifor; and is a speaker for AIO Studien gGmbH, BMS, Lilly, and MCI. Marino Venerito received honoraria for speaker, consultancy, advisory role, and\/or research grants from Servier, Roche, BMS, MSD, EISAI, Bayer, Lilly, AstraZeneca, Merck Serono, Sirtex, Ipsen, Nordic Pharma, and Amgen. Ulli Bankstahl, Claudia Pauligk, Maria Loose, and Nils Homann have no conflicts of interest to declare. Possible conflicts of other authors tbn.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}